DrugPatentWatch Database Preview
Drugs in Development Information for ASP1517
Email this page to a colleague
» See Plans and PricingWhat is the drug development status for ASP1517?
ASP1517 is an investigational drug.
There have been 24 clinical trials for ASP1517.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2013.
The most common disease conditions in clinical trials are Anemia, Renal Insufficiency, Chronic, and Kidney Diseases. The leading clinical trial sponsors are FibroGen, Astellas Pharma Inc, and Astellas Pharma Europe B.V.
There are twenty-eight US patents protecting this investigational drug and one hundred and ninety-nine international patents.
Summary for ASP1517
| US Patents | 28 |
| International Patents | 199 |
| US Patent Applications | 59 |
| WIPO Patent Applications | 35 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2013-05-01) |
| Vendors | 73 |
Recent Clinical Trials for ASP1517
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation i | FibroGen | Phase 1 |
| A Study to Assess the Relative Bioavailability of Roxadustat Following a Single Dose of Pediatric Azo Dye-free Tablet Formulation and Pediatric Azo Dye-free Mini-tablet Formulation Compared to a Single Dose of Azo Dye-containing Tablet Formulation i | Astellas Pharma Global Development, Inc. | Phase 1 |
| Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden | AstraZeneca | Phase 3 |
Clinical Trial Summary for ASP1517
Top disease conditions for ASP1517
Top clinical trial sponsors for ASP1517
US Patents for ASP1517
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ASP1517 | Start Trial | Nitrogen-containing heteroaryl compounds and methods of use thereof | FibroGen, Inc. (San Francisco, CA) | Start Trial |
| ASP1517 | Start Trial | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen, Inc. (San Francisco, CA) | Start Trial |
| ASP1517 | Start Trial | Crystalline forms of a prolyl hydroxylase inhibitor | FibroGen, Inc. (San Francisco, CA) | Start Trial |
| ASP1517 | Start Trial | Nitrogen-containing heteroaryl compounds and methods of use thereof | Fibrogen, Inc. (South San Francisco, CA) | Start Trial |
| ASP1517 | Start Trial | Nitrogen-containing heteroaryl compounds and methods of user thereof | FibroGen, Inc. (San Francisco, CA) | Start Trial |
| ASP1517 | Start Trial | Compounds and methods for treatment of chemotherapy-induced anemia | FibroGen, Inc. (San Francisco, CA) | Start Trial |
| ASP1517 | Start Trial | Nitrogen-containing heteroaryl compounds and methods of use thereof | FibroGen, Inc. (San Francisco, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ASP1517
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ASP1517 | Austria | 496033 | 2023-06-06 | Start Trial |
| ASP1517 | Australia | 2004245552 | 2023-06-06 | Start Trial |
| ASP1517 | Brazil | PI0411055 | 2023-06-06 | Start Trial |
| ASP1517 | Canada | 2528232 | 2023-06-06 | Start Trial |
| ASP1517 | China | 102718708 | 2023-06-06 | Start Trial |
| ASP1517 | China | 102977015 | 2023-06-06 | Start Trial |
| ASP1517 | China | 102977016 | 2023-06-06 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
